000739 普洛药业
2025/12 -
人民幣(K¥)

变动
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入9,783,601-18.62%11,474,16210,544,9058,942,6187,879,673
减:营业总成本8,789,065-19.06%10,231,0129,468,4907,923,6797,089,606
    其中:营业成本7,204,943-21.30%8,529,4558,024,2296,552,2775,676,632
               财务费用(58,756)-48.98%(104,372)(105,749)(14,296)66,530
               资产减值损失(95,921)36.59%(91,833)(51,158)(26,388)(23,775)
公允价值变动收益----(19)(22,838)(23,617)47,447
投资收益19,781-209.33%(21,685)(59,768)90,35262,018
    其中:对联营企业和合营企业的投资收益(16,227)-367.93%3,2664,15912,86847,656
营业利润1,070,864-11.65%1,220,1421,011,6231,119,355969,706
利润总额1,066,199-11.39%1,204,6441,012,0651,114,080961,153
减:所得税费用175,5171.78%149,33722,894158,530144,423
净利润890,682-13.60%1,055,307989,171955,550816,730
减:非控股权益4-101.35%(34)(3)----
股东净利润890,678-13.62%1,055,341989,174955,550816,730

市场价值指针
每股收益 (元) *0.772-12.87%0.9030.8430.8110.693
每股派息 (元) *0.58664.68%0.3170.2970.2850.243
每股净资产 (元) *5.472-5.10%5.2804.6774.2943.726
审计意见 #标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容